Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q35829430

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Simultaneous and rapid determi ...... th non-small-cell lung cancer.

@ast

Simultaneous and rapid determi ...... th non-small-cell lung cancer.

@en

type

Item

label

Simultaneous and rapid determi ...... th non-small-cell lung cancer.

@ast

Simultaneous and rapid determi ...... th non-small-cell lung cancer.

@en

prefLabel

Simultaneous and rapid determi ...... th non-small-cell lung cancer.

@ast

Simultaneous and rapid determi ...... th non-small-cell lung cancer.

@en

P1476

Simultaneous and rapid determi ...... th non-small-cell lung cancer.

@en

P2093

Chiemi Hirose

http://www.w3.org/2001/XMLSchema#string

Hideki Hayashi

http://www.w3.org/2001/XMLSchema#string

Kenichiro Todoroki

http://www.w3.org/2001/XMLSchema#string

Kiyoyuki Kitaichi

http://www.w3.org/2001/XMLSchema#string

Koumei Yanase

http://www.w3.org/2001/XMLSchema#string

Maya Yamada

http://www.w3.org/2001/XMLSchema#string

Shinya Minatoguchi

http://www.w3.org/2001/XMLSchema#string

Tadashi Sugiyama

http://www.w3.org/2001/XMLSchema#string

Yasushi Ohno

http://www.w3.org/2001/XMLSchema#string

Yoshinori Itoh

http://www.w3.org/2001/XMLSchema#string

P2860

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials.

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

P304

1150-1154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BMC.3642

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hirotoshi Iihara

P577

2015-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26525154

http://www.w3.org/2001/XMLSchema#string